Attovia holder converts Series C preferred to common

Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. insider Deep Track Biotechnology Master Fund, Ltd. reported the automatic conversion of Series C Redeemable Convertible Preferred Stock into common stock in connection with the closing of Attovia’s initial public offering. 18,181,818 preferred shares converted into 1,957,138 common shares at a 9.29-for-one ratio, resulting in 1,957,138 common shares held directly. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but each disclaims beneficial ownership beyond their respective pecuniary interests.

Insider Trade Summary

18,181,818 shares exercised/converted

Exercise 2 txns

Insider Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, KROIN DAVID

Role 10% Owner | 10% Owner | 10% Owner

Type	Security	Shares	Price	Value
Conversion	Series C Redeemable Convertible Preferred Stock F1, F2	18,181,818	$0.00	$0.00
Conversion	Common Stock F1, F2	1,957,138	--	--

Holdings After Transaction: Series C Redeemable Convertible Preferred Stock — 0 contracts (Direct); Common Stock — 1,957,138 shares (Direct)

Footnotes (2)

1. F1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.
2. F2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Key Figures

Series C preferred shares converted: 18,181,818 shares Common shares received: 1,957,138 shares Conversion ratio: 9.29-for-one +1 more

4 metrics

Series C preferred shares converted 18,181,818 shares Automatic conversion of Series C Redeemable Convertible Preferred Stock upon IPO closing

Common shares received 1,957,138 shares Common stock issued to Deep Track Biotechnology Master Fund, Ltd. from preferred conversion

Conversion ratio 9.29-for-one Each share of Series C Redeemable Convertible Preferred Stock converted into common stock

Common shares held after conversion 1,957,138 shares Direct ownership reported following the conversion transaction

Key Terms

Series C Redeemable Convertible Preferred Stock, initial public offering, conversion ratio, pecuniary interests

4 terms

Series C Redeemable Convertible Preferred Stock financial

"Each share of Series C Redeemable Convertible Preferred Stock automatically converted"

initial public offering financial

"automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

conversion ratio financial

"upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one"

The conversion ratio is the number of common shares an investor receives when a convertible security (like a bond or preferred share) or an exchangeable instrument is turned into ordinary stock. It matters because it tells investors how much ownership or dilution will occur — similar to knowing how many slices you get when you trade in a coupon — and directly affects the value you get from the convertible and the company’s future share count.

pecuniary interests financial

"disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Attovia Therapeutics (ATTO) report on this Form 4?

Deep Track Biotechnology Master Fund, Ltd. reported an automatic conversion of Series C Redeemable Convertible Preferred Stock into Attovia common stock upon the IPO closing, receiving 1,957,138 common shares from 18,181,818 preferred shares.

How many Attovia Therapeutics (ATTO) preferred shares were converted and into how many common shares?

The filing states that 18,181,818 shares of Series C Redeemable Convertible Preferred Stock converted into 1,957,138 shares of common stock, reflecting a specified 9.29-for-one conversion ratio tied to Attovia’s initial public offering.

What is Deep Track Biotechnology Master Fund, Ltd.’s resulting Attovia (ATTO) common stock holding?

After the reported conversion, Deep Track Biotechnology Master Fund, Ltd. holds 1,957,138 shares of Attovia common stock directly. This position reflects the automatic conversion of its Series C preferred shares at the IPO-related conversion ratio.

Who are the reporting persons on the Attovia Therapeutics (ATTO) Form 4 and what are their roles?

The reporting persons are Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, and David Kroin. Deep Track Capital, LP manages the fund, and Mr. Kroin is managing member of the fund’s general partner, with each disclaiming beneficial ownership beyond pecuniary interests.

Was the Attovia Therapeutics (ATTO) Form 4 transaction a market buy or sell?

No market buy or sell is reported. The Form 4 describes an automatic conversion of preferred stock into common stock upon Attovia’s IPO closing, a structural change in security form rather than an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deep Track Biotechnology Master Fund, Ltd.

(Last) (First) (Middle)

C/O WALKERS CORPORATE LIMITED

190 ELGIN AVE

(Street)

GEORGE TOWN CAYMAN ISLANDS KY1-9001

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		C		1,957,138	A	(1)	1,957,138	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Redeemable Convertible Preferred Stock	(1)	08/06/2026		C			18,181,818	(1)	(1)	Common Stock	1,957,138	$0	$0	D(2)

1. Name and Address of Reporting Person^*

Deep Track Biotechnology Master Fund, Ltd.

(Last) (First) (Middle)

C/O WALKERS CORPORATE LIMITED

190 ELGIN AVE

(Street)

GEORGE TOWN CAYMAN ISLANDS KY1-9001

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Deep Track Capital, LP

(Last) (First) (Middle)

200 GREENWICH AVENUE, 3RD FLOOR

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

KROIN DAVID

(Last) (First) (Middle)

C/O DEEP TRACK CAPITAL, LP, 200

GREENWICH AVENUE, 3RD FLOOR

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

	Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin, Director	08/10/2026
	Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser	08/10/2026
	/s/ David Kroin	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)